The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or ...

The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.

Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the ...

Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve retention in crowded GLP-1 market. Millions of people on GLP-1 weight-loss ...

FRANKFURT (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose ...

Atropine is a muscarinic antagonist and is indicated for temporary blockage of severe or life threatening muscarinic effects. Atropine Sulfate Injection is now available in an 8mg per 20mL ...

Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, ...

(RTTNews) - Amphastar Pharmaceuticals Inc. (AMPH) announced Tuesday that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application or ANDA for Succinylcholine Chloride ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.